Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS)

Clinical Neuropharmacology

Volumn 36, Issue 2, 2013, Pages 59-62

  Novakovic, Vladan ^a   Adel, Tymaz ^b   Peselow, Eric ^c   Lindenmayer, Jean Pierre ^d  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b ST GEORGE S UNIVERSITY SCHOOL OF MEDICINE   (Grenada)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ong acting injectable antipsychotics; PDSS; postinjection delirium sedation syndrome

Indexed keywords

OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

ARTICLE; CONFUSION; DATA BASE; DELIRIUM; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GAIT DISORDER; HUMAN; MALAISE; MENTAL DISEASE; POSTINJECTION DELIRIUM SEDATION SYNDROME; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TREATMENT FAILURE; UNCONSCIOUSNESS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DELIRIUM; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAMUSCULAR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNDROME;

EID: 84875413162     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182854f70     Document Type: Article

References (11)

1. Schizophrenia [World Health OrganizationWeb site]. 2012. Available at: http://www.who.int/mental-health/management/schizophrenia/en/. Accessed October 28, 2012.
2. Stroup TS, Marder S. Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment [UpToDate Web site]. October 23, 2012. Available at: http://www.uptodate.com/contents/pharmacotherapy-forschizophrenia-acute-and- maintenance-phase-treatment. Accessed October 29, 2012.
3. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(Suppl 5):15-18.
4. McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 2010;10:45.
5. Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010;10:43.
6. Alphs L, Gopal S, Karcher K, et al. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome An assessment of safety databases. Curr Drug Saf 2011;6:43-45.
7. Owen RT. Paliperidone palmitate injection: its efficacy, safety and tolerability in schizophrenia. Drugs Today 2010;46(7):463-471.
8. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167(2):181-189.
9. Important Safety Information about ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension. August 31, Available at: https://www.zyprexarelprevvprogram.com/public/OD%20HCP%20ISI%2031AUG2012.pdf. Accessed October 19, 2012.
10. Lauriello J, McEvoy JP, Rodriguez S, et al. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research 2005;72:249-258.
11. Citrome L. Olanzapine pamoate: a stick in time A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009; 63(1):140-150.